↓ Skip to main content

Acute Leukemias

Overview of attention for book
Cover of 'Acute Leukemias'

Table of Contents

  1. Altmetric Badge
    Book Overview
  2. Altmetric Badge
    Chapter 1 Cell Kinetics in Leukemia and Preleukemia
  3. Altmetric Badge
    Chapter 2 Acute Nonlymphocytic Leukemia in Adults: Pathophysiology, Status of Current Therapy, and New Approaches
  4. Altmetric Badge
    Chapter 3 Prognostic Significance of Chromosome Changes in Acute Leukemia
  5. Altmetric Badge
    Chapter 4 Morphological and cytochemical classification of adult acute leukemias in two multicenter studies in the Federal Republic of Germany.
  6. Altmetric Badge
    Chapter 5 Therapeutic Strategies in Acute Myelocytic Leukemia: A Status Report of the Experience of CALGB
  7. Altmetric Badge
    Chapter 6 The ninth British Medical Research Council trial for the treatment of acute myeloid leukaemia.
  8. Altmetric Badge
    Chapter 7 Long-term results of two Swiss AML studies.
  9. Altmetric Badge
    Chapter 8 Prediction of induction and duration of complete remission in acute myelogenous leukemia: value of clonogenic cell properties.
  10. Altmetric Badge
    Chapter 9 Remission induction and maintenance modalities in acute myeloid leukemia: a multicenter randomized study.
  11. Altmetric Badge
    Chapter 10 Postinduction and preremission chemotherapy alternatives for adult AML: three multicenter studies of the AML Cooperative Group.
  12. Altmetric Badge
    Chapter 11 Neuraminidase-treated allogeneic blasts for maintenance in acute myelogenous leukemia: results of a prospective randomized trial.
  13. Altmetric Badge
    Chapter 12 The childhood AML studies BFM-78 and -83: treatment results and risk factor analysis.
  14. Altmetric Badge
    Chapter 13 Improved treatment results in childhood acute nonlymphoblastic leukemia with the BFM-AML protocol 78 in a multicenter study in the GDR.
  15. Altmetric Badge
    Chapter 14 A comparison of cytokinetically based versus intensive chemotherapy for childhood acute myelogenous leukemia.
  16. Altmetric Badge
    Chapter 15 Postremission induction intensive sequential chemotherapy for children with AML--treatment results and prognostic factors.
  17. Altmetric Badge
    Chapter 16 Clinical Relevance of Blast Cell Phenotype as Determined with Monoclonal Antibodies in Acute Lymphoblastic Leukemia of Adults
  18. Altmetric Badge
    Chapter 17 Risk Groups in Adult Acute Lymphoblastic Leukemia
  19. Altmetric Badge
    Chapter 18 Prognostic factors in acute lymphoblastic leukemia in adults: the Memorial Hospital experience.
  20. Altmetric Badge
    Chapter 19 Treatment of Adult Acute Lymphoblastic Leukemia. Preliminary Results of a Trial from the French Group
  21. Altmetric Badge
    Chapter 20 Therapy for Adolescent and Adult Acute Lymphoblastic Leukemia: Randomization of Induction and Consolidation Therapies (Preliminary Results of EORTC Study 58791)
  22. Altmetric Badge
    Chapter 21 Therapy Results in Five ALL-BFM Studies Since 1970: Implications of Risk Factors for Prognosis
  23. Altmetric Badge
    Chapter 22 The BFM Relapse Studies in Childhood ALL: Concepts of Two Multicenter Trials and Results after 21/2 Years
  24. Altmetric Badge
    Chapter 23 Limiting Toxicities During Intensified Remission Induction Chemotherapy for Childhood Acute Lymphocytic Leukemia
  25. Altmetric Badge
    Chapter 24 Stratification by Prognostic Factors in the Design and Analysis of Clinical Trials for Acute Lymphoblastic Leukemia
  26. Altmetric Badge
    Chapter 25 Strategies for the Treatment of Children with Acute Lymphoblastic Leukemia and Unfavorable Presenting Features
  27. Altmetric Badge
    Chapter 26 Infection Prevention and Immediate Antibiotic Therapy in the Neutropenic Patient
  28. Altmetric Badge
    Chapter 27 Special Aspects of Supportive Therapy in Childhood Acute Leukemias
  29. Altmetric Badge
    Chapter 28 Prevention of Infection in Patients with Acute Nonlymphocytic Leukemia by Several Drug Treatment Regimens
  30. Altmetric Badge
    Chapter 29 The role of bone marrow transplantation in acute myelogenous leukemia.
  31. Altmetric Badge
    Chapter 30 Allogeneic marrow transplantation for treatment of leukemia: results of the Munich Cooperative Group.
  32. Altmetric Badge
    Chapter 31 Bone marrow transplantation in acute leukemia.
  33. Altmetric Badge
    Chapter 32 Bone Marrow Transplantation in Childhood Leukemia in West Germany
  34. Altmetric Badge
    Chapter 33 Allogeneic, Syngeneic, and Autologous Bone Marrow Transplantation in the Acute Leukemias — Baltimore Experience
  35. Altmetric Badge
    Chapter 34 Treatment of patients with acute myeloid leukemia in first remission with marrow ablative therapy and autologous bone marrow transplantation.
  36. Altmetric Badge
    Chapter 35 Modification of tRNA and Its Applicability for the Assessment of Prognosis, State of Differentiation, and Clonality in Human Leukemias and Lymphomas
  37. Altmetric Badge
    Chapter 36 Immunoglobulin and T Cell Receptor Gene Rearrangements in Acute Leukemias
  38. Altmetric Badge
    Chapter 37 Abnormal production and release of ferritin by immature myeloid cells in leukemia.
  39. Altmetric Badge
    Chapter 38 Induction of Early Myeloperoxidase in Acute Unclassified Leukemia
  40. Altmetric Badge
    Chapter 39 Abnormal marker expression in acute leukemia (AL) characterized by monoclonal antibodies and flow cytometry.
  41. Altmetric Badge
    Chapter 40 Urinary GP41 excretion in patients with acute leukemias treated with intensive induction polychemotherapy.
  42. Altmetric Badge
    Chapter 41 Toxicity and Mutagenicity of 6 Anti-Cancer Drugs in Chinese Hamster Cells Co-Cultured with Rat Hepatocytes
  43. Altmetric Badge
    Chapter 42 Pharmacokinetics of daunorubicin as a determinant of response in acute myeloid leukemia.
  44. Altmetric Badge
    Chapter 43 Pharmacokinetic study of cytosine arabinoside in patients with acute myelogeneous leukemia.
  45. Altmetric Badge
    Chapter 44 Pharmacokinetics of Oral Methotrexate in Bone Marrow During Maintenance Treatment of Childhood Acute Lymphocytic Leukemia
  46. Altmetric Badge
    Chapter 45 Determination of the cellular uptake of daunorubicin in human leukemia in vivo: method of examination and first results.
  47. Altmetric Badge
    Chapter 46 Cytoskeletal organization in acute leukemias.
  48. Altmetric Badge
    Chapter 47 Pitfalls in the Evaluation of Prognostic Factors
  49. Altmetric Badge
    Chapter 48 Low-Dose Ara-C in Myelodysplastic Syndromes and Acute Nonlymphoid Leukemia. Experience with Seven Patients
  50. Altmetric Badge
    Chapter 49 Low-dose cytosine arabinoside in patients with acute myeloblastic leukemia and myelodysplastic syndrome.
  51. Altmetric Badge
    Chapter 50 Low-dose Ara-C treatment in elderly patients with acute myeloblastic leukemia.
  52. Altmetric Badge
    Chapter 51 Acute leukaemia in the elderly, remission induction versus palliative therapy.
  53. Altmetric Badge
    Chapter 52 The Use of Amsacrine plus Intermediate-Dose Cytosine Arabinoside in Relapsed and Refractory Acute Nonlymphocytic Leukemia
  54. Altmetric Badge
    Chapter 53 Phase I/II trial of high-dose cytosine arabinoside and mitoxantrone in adult refractory acute myeloid leukemia.
  55. Altmetric Badge
    Chapter 54 Mitoxantrone and VP-16 in refractory acute myelogenous leukemia.
  56. Altmetric Badge
    Chapter 55 4-Demethoxydaunorubicin (idarubicin) in relapsed and refractory acute myeloid leukemia.
  57. Altmetric Badge
    Chapter 56 Intensive induction and consolidation chemotherapy for adults and children with acute myeloid leukaemia (AML) joint AML trial 1982-1985.
  58. Altmetric Badge
    Chapter 57 Remission induction with cytarabine and daunorubicin with or without 6-thioguanine in adult patients with acute myelocytic leukemia.
  59. Altmetric Badge
    Chapter 58 Contribution of clonogenic leukemic cell characteristics to therapy outcome in patients with acute myeloblastic leukemia.
  60. Altmetric Badge
    Chapter 59 Expression of CD-15 Antigen on Leukemic Cells — A New Prognostic Factor for Ability to Achieve Complete Remission and for Survival in ANLL
  61. Altmetric Badge
    Chapter 60 Prognostic Significance of Morphologic and Cytogenetic Findings for Progression in Myelodysplastic Syndromes
  62. Altmetric Badge
    Chapter 61 Analysis of prognostic factors in acute leukemias in adults.
  63. Altmetric Badge
    Chapter 62 Acute myelocytic leukemia in adults: a long-term analysis.
  64. Altmetric Badge
    Chapter 63 Prognostic factors in acute myelogenous leukemia.
  65. Altmetric Badge
    Chapter 64 Serum Zinc and Copper as Prognostic Factors in Acute Nonlymphocytic Leukemia
  66. Altmetric Badge
    Chapter 65 Immunological monitoring in remission acute myeloid leukemia during maintenance therapy.
  67. Altmetric Badge
    Chapter 66 Treatment of Childhood Acute Nonlymphocytic Leukemia with Individually Scheduled High Doses of Cytarabine: Preliminary Results of Study ANLL-82 of the Dutch Childhood Leukemia Study Group (DCLSG)
  68. Altmetric Badge
    Chapter 67 Aclacinomycin-A in the induction treatment of childhood acute myelogenous leukemia.
  69. Altmetric Badge
    Chapter 68 High-dose cytosine arabinoside and retinol in the treatment of acute myelogenous leukemia in childhood.
  70. Altmetric Badge
    Chapter 69 CHOP treatment of childhood acute myelogenous leukemia with monocytic differentiation: a report on five cases.
  71. Altmetric Badge
    Chapter 70 Effective remission induction in children with recurrent acute myeloid leukemia by mAMSA, Ara-C, and VP 16.
  72. Altmetric Badge
    Chapter 71 Alteration of blast phenotype after low-dose cytarabine in children with acute myeloid leukemia.
  73. Altmetric Badge
    Chapter 72 Biphenotypic Leukemia in Childhood: Presentation of Five Cases
  74. Altmetric Badge
    Chapter 73 Surface marker analysis by monoclonal antibodies: a valuable technique in childhood acute myeloid leukemia.
  75. Altmetric Badge
    Chapter 74 Infant leukemia: a single pattern of nonlymphocytic leukemia?
  76. Altmetric Badge
    Chapter 75 Growth of Children with Acute Lymphocytic Leukemia: Preliminary Results
  77. Altmetric Badge
    Chapter 76 Two Unexpected Courses in Four Children with Lymphoblastic Leukemia of B-Cell Type (B-ALL)
  78. Altmetric Badge
    Chapter 77 Progress in treatment of children with non-Hodgkin lymphoma: a report of the Polish Leukemia and Lymphoma Study Group.
  79. Altmetric Badge
    Chapter 78 Addition of Rubidomycin to Induction Treatment with Vincristine, Prednisone, and l -Asparaginase in Standard-Risk Childhood Acute Lymphocytic Leukemia (Study ALL V): A Report on Behalf of the Dutch Childhood Leukemia Study Group
  80. Altmetric Badge
    Chapter 79 Medical Research Council Childhood Leukaemia Trial VIII Compared with Trials II–VII: Lessons for Future Management
  81. Altmetric Badge
    Chapter 80 Early Intensification Therapy in High-Risk Childhood Acute Lymphocytic Leukemia: Lack of Benefit from High-Dose Methotrexate
  82. Altmetric Badge
    Chapter 81 Intermediate-Risk Childhood Acute Lymphoblastic Leukemias: Amsacrine + Cytosine Arabinoside Versus Intermediate-Dose Methotrexate for Consolidation, and 6-Mercaptopurine + Methotrexate + Vincristine Versus Monthly Pulses for Maintenance
  83. Altmetric Badge
    Chapter 82 Treatment of Acute Lymphoblastic Leukemia in Children with the BFM Protocol: A Cooperative Study and Analysis of Prognostic Factors
  84. Altmetric Badge
    Chapter 83 Results of Acute Lymphoblastic Leukemia Therapy in Childhood with a Modified BFM Protocol in a Multicenter Study in the German Democratic Republic
  85. Altmetric Badge
    Chapter 84 Intensive Therapy in Childhood Acute Lymphoblastic Leukemia: A Report from the Polish Children’s Leukemia and Lymphoma Study Group After 11 Years
  86. Altmetric Badge
    Chapter 85 Treatment of Standard- and High-Risk Childhood Acute Lymphoblastic Leukaemia with Two CNS Prophylaxis Regimens
  87. Altmetric Badge
    Chapter 86 Aggressive Combination Chemotherapy of Bone Marrow Relapse in Childhood Acute Lymphoblastic Leukemia Containing Aclacinomycin-A: A Multicentric Trial
  88. Altmetric Badge
    Chapter 87 Prognostic Meaning of Chromosome Aberrations in Acute Lymphocytic Leukemia and Acute Nonlymphocytic Leukemia Patients of the BFM Study Group
  89. Altmetric Badge
    Chapter 88 Karyotype, Immunophenotype, and Clinical Outcome: Correlations in Childhood Acute Lymphoblastic Leukemia
  90. Altmetric Badge
    Chapter 89 DNA Aneuploidy in Children with Relapsed Acute Lymhoblastic Leukemia as Measured by Flow Cytometry
  91. Altmetric Badge
    Chapter 90 Hyperdiploid Childhood Acute Lymphocytic Leukemia: Cellular Properties and Prognostic Implications
  92. Altmetric Badge
    Chapter 91 Intensive Care Therapy for Patients with Hematological Diseases
  93. Altmetric Badge
    Chapter 92 The problem of early death in childhood AML.
  94. Altmetric Badge
    Chapter 93 Passive and active anti-hepatitis B immunization of children with hematological malignancies.
  95. Altmetric Badge
    Chapter 94 Increased Awareness of Aspergillosis in Acute Leukemia Patients
  96. Altmetric Badge
    Chapter 95 Cytomegalovirus Hyperimmunoglobulin and Substitution with Blood Products from Antibody-Negative Donors. A Pilot Study in Bone Marrow Transplant Recipients
  97. Altmetric Badge
    Chapter 96 Prophylactic Application of an Anti-Cytomegalovirus Hyperimmunoglobulin in Allogeneic Bone Marrow Transplant Recipients
  98. Altmetric Badge
    Chapter 97 Incidence and treatment of fungal infections in neutropenic patients.
  99. Altmetric Badge
    Chapter 98 First experiences with a permanent catheter system in acute leukemia.
  100. Altmetric Badge
    Chapter 99 On the fate of leukemic cells infused with the autologous marrow graft.
  101. Altmetric Badge
    Chapter 100 Hematological Reconstitution After Autologous Peripheral Blood Transplantation
  102. Altmetric Badge
    Chapter 101 Depletion of T Cells from Bone Marrow Grafts with Soybean Agglutinin and Sheep Red Blood Cells for Prevention of Graft-Versus-Host Disease
  103. Altmetric Badge
    Chapter 102 Bone Marrow Transplantation for Chronic Granulocytic Leukemia: Results of the French Cooperative Group (GEGMO)
  104. Altmetric Badge
    Chapter 103 An HLA lost mutation may lead to leukemic relapse of recipient type six years after bone marrow transplantation.
  105. Altmetric Badge
    Chapter 104 Toxoplasmosis after bone marrow transplantation.
Overall attention for this book and its chapters
Altmetric Badge

Mentioned by

policy
1 policy source

Citations

dimensions_citation
13 Dimensions
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Acute Leukemias
Published by
Springer Berlin Heidelberg, January 1987
DOI 10.1007/978-3-642-71213-5
ISBNs
978-3-54-016556-9, 978-3-64-271213-5
Editors

Büchner, T., Schellong, G., Hiddemann, W., Urbanitz, D., Ritter, J.